Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BYAH · Nasdaq · United States · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
In shortPark Ha Biological Technology Co., Ltd. is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -956.5% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -965.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -885.8% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.92× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -588997.59× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -34.37 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -0.1% | 20/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 4 | 69/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 4 | 75/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 3 | 44/100 |
| Revenue growth volatility | 16.1% | 52/100 |
| Operating margin volatility | 493.7% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 9.6% | 70/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 1.9 | 2.5 | 2.4 | 2.5 |
| Cost of revenue | 0.5 | 0.3 | 0.2 | 0.1 |
| Gross profit | 1.4 | 2.1 | 2.2 | 2.4 |
| Research & development | 0.1 | 0 | 0 | 0.2 |
| Operating income | 0.2 | 1.2 | 0.8 | (24) |
| Interest expense | 0 | – | – | 0 |
| Pre-tax income | 0.2 | 1.2 | 0.8 | (24) |
| Income tax | (0) | 0.3 | 0.3 | 0.3 |
| Net income | 0.2 | 0.9 | 0.5 | (24) |
| Diluted EPS | $0.01 | $1.70 | $0.96 | −$41.38 |
| Diluted shares (millions) | 25 | 0.5 | 0.5 | 0.6 |
−34.37 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Oct 31, 2025 · Data updated May 15, 2026